Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 4, Pages e1008814
Publisher
Informa UK Limited
Online
2015-05-28
DOI
10.1080/2162402x.2015.1008814
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer and the gut microbiota: An unexpected link
- (2015) Laurence Zitvogel et al. Science Translational Medicine
- Trial Watch: Peptide-based anticancer vaccines
- (2015) Jonathan Pol et al. OncoImmunology
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients
- (2014) M Konstantinou et al. ACTA DERMATO-VENEREOLOGICA
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Adoptive Immunotherapy for Cancer or Viruses
- (2014) Marcela V. Maus et al. Annual Review of Immunology
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
- (2014) V Chiarion-Sileni et al. BRITISH JOURNAL OF CANCER
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
- (2014) Y. Saenger et al. CLINICAL CANCER RESEARCH
- Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
- (2014) M. Dai et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Impact of myeloid cells on the efficacy of anticancer chemotherapy
- (2014) Laura Senovilla et al. CURRENT OPINION IN IMMUNOLOGY
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
- (2014) Emma D. Deeks DRUGS
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
- (2014) Andreas Herrmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
- (2014) Vanna Chiarion Sileni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
- (2014) Shravan Madireddi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
- (2014) Sven de Vos et al. Journal of Hematology & Oncology
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Pembrolizumab for treatment of refractory melanoma
- (2014) Sanjeet Bagcchi LANCET ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Protein kinase C-η controls CTLA-4–mediated regulatory T cell function
- (2014) Kok-Fai Kong et al. NATURE IMMUNOLOGY
- Smart therapeutic strategies in immuno-oncology
- (2014) Alexander M. M. Eggermont et al. Nature Reviews Clinical Oncology
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- Curcumin Significantly Enhances Dual PI3K/Akt and mTOR Inhibitor NVP-BEZ235-Induced Apoptosis in Human Renal Carcinoma Caki Cells through Down-Regulation of p53-Dependent Bcl-2 Expression and Inhibition of Mcl-1 Protein Stability
- (2014) Bo Ram Seo et al. PLoS One
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- PD-1 Inhibitor Approved for Melanoma
- (2014) Cancer Discovery
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Finding a needle in a haystack
- (2014) Qunrui Ye et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma
- (2014) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2014) Jonathan Pol et al. OncoImmunology
- Novel insights into the mechanism of action of lenalidomide
- (2014) Michaela Semeraro et al. OncoImmunology
- Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer
- (2014) Aizea Morales-Kastresana et al. OncoImmunology
- Combined OX40 ligation plus CTLA-4 blockade
- (2014) Stefanie N Linch et al. OncoImmunology
- Immune response markers in sentinel nodes may predict melanoma progression
- (2014) Monica Rodolfo et al. OncoImmunology
- A novel combinatorial cancer immunotherapy
- (2014) Toshihiro Nagato et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Trial Watch: Radioimmunotherapy for oncological indications
- (2014) Norma Bloy et al. OncoImmunology
- Immune checkpoints
- (2014) Akhil Chawla et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
- (2014) Huafeng Wei et al. OncoImmunology
- Trial watch
- (2014) Erika Vacchelli et al. OncoImmunology
- The immune landscape of human tumors
- (2014) Gabriela Bindea et al. OncoImmunology
- PD-L1 expression and tumor-infiltrating lymphocytes
- (2014) Kurt A Schalper OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Trial watch: Dendritic cell-based anticancer therapy
- (2014) Norma Bloy et al. OncoImmunology
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Trial Watch:
- (2014) Jonathan Pol et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Predictive immunomonitoring — The COST ENTIRE initiative
- (2013) Dusan Popadic et al. CLINICAL IMMUNOLOGY
- The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
- (2013) Amy E Moran et al. CURRENT OPINION IN IMMUNOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Dendritic-Cell-Based Therapeutic Cancer Vaccines
- (2013) Karolina Palucka et al. IMMUNITY
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
- (2013) Maresa Altomonte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Immunological checkpoint inhibitors enter adolescence
- (2013) Anna K Nowak LANCET ONCOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Adoptive cell therapy: Honing that killer instinct
- (2013) Courtney Humphries NATURE
- Surgery for NSCLC in the era of personalized medicine
- (2013) Tetsuya Mitsudomi et al. Nature Reviews Clinical Oncology
- Image-guided cancer surgery using near-infrared fluorescence
- (2013) Alexander L. Vahrmeijer et al. Nature Reviews Clinical Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
- (2013) A Q Butt et al. ONCOGENE
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- Ipilimumab and radiation therapy for melanoma brain metastases
- (2013) Ann W. Silk et al. Cancer Medicine
- Assessing T-cell responses in anticancer immunotherapy
- (2013) David Escors et al. OncoImmunology
- Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
- (2013) Sandra Demaria et al. OncoImmunology
- Immune correlates of melanoma survival in adoptive cell therapy
- (2013) Agnes Fermin Lee et al. OncoImmunology
- Current trends of anticancer immunochemotherapy
- (2013) Erika Vacchelli et al. OncoImmunology
- Prognostic value of the immune microenvironment in lung adenocarcinoma
- (2013) Kyuichi Kadota et al. OncoImmunology
- Trial Watch: Lenalidomide-based immunochemotherapy
- (2013) Michaela Semeraro et al. OncoImmunology
- Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
- (2013) Weiyi Peng et al. OncoImmunology
- Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
- (2013) Haval Shirwan et al. OncoImmunology
- Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I
- (2013) Max Schnurr et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Re-orienting the immune system
- (2013) Evan J. Lipson OncoImmunology
- Development of interferon γ-based immunocytokines targeting renal cancer
- (2013) Peirong Chen et al. OncoImmunology
- Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
- (2013) Jessica Ann Chacon et al. OncoImmunology
- Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
- (2013) Hojabr Kakavand et al. OncoImmunology
- Inhibiting the inhibitors
- (2013) Domenico Mavilio et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Immunogenic cell death in radiation therapy
- (2013) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch
- (2013) Laura Senovilla et al. OncoImmunology
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- (2013) Liza B John et al. OncoImmunology
- Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
- (2013) Zachary A. Cooper et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
- (2013) Sherene Loi OncoImmunology
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
- (2013) Brian Baldo OncoImmunology
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward
- (2012) Anatoli Malyguine et al. Journal of Immunotoxicology
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
- (2012) Antoni Ribas et al. Journal of Translational Medicine
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Abscopal Effect in a Patient with Melanoma
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- Trial watch
- (2012) Laura Senovilla et al. OncoImmunology
- Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
- (2012) Roch Houot et al. OncoImmunology
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
- (2012) Adam J. Adler et al. OncoImmunology
- OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
- (2011) David R. Withers et al. IMMUNOLOGICAL REVIEWS
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- Ipilimumab
- (2011) Vernon K. Sondak et al. NATURE REVIEWS DRUG DISCOVERY
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- B regulatory cells and the tumor-promoting actions of TNF- during squamous carcinogenesis
- (2011) T. Schioppa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunity unleashed in melanoma
- (2010) Michael K Erdmann LANCET ONCOLOGY
- Alternatives to surgery after failure of instillation therapy
- (2010) Christian Weiss et al. Nature Reviews Clinical Oncology
- Ipilimumab success in melanoma provides boost for cancer immunotherapy
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Mechanisms maintaining peripheral tolerance
- (2009) Daniel L Mueller NATURE IMMUNOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells
- (2008) Nathalie T. Joncker et al. IMMUNOLOGICAL REVIEWS
- Negative signaling by inhibitory receptors: the NK cell paradigm
- (2008) Eric O. Long IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now